A random forest model predicts responses to infliximab in Crohn's disease based on clinical and serological parameters.

A novel random forest model using the clinical and serological parameters of baseline data was established to identify CD patients with baseline inflammation to achieve IFX response. This model could be valuable for physicians, patients and insurers, which allows individualised therapy.